Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq touch new peaks as Treasury yields cool, oil slips
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
| Beam Inc. (NASDAQ: BEAM) | Delayed: 25.81 +0.14 (0.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.67 | 52 Week High | $83.60 | |||
| Open | $26.80 | 52 Week Low | $82.96 | |||
| Day High | $26.94 | P/E | 11.52 | |||
| Day Low | $24.87 | EPS | $2.24 | |||
| Volume | 1,300,770 | |||||
| Beam Inc. (NASDAQ: BEAM) | Delayed: 25.81 +0.14 (0.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.67 | 52 Week High | $83.60 | |||
| Open | $26.80 | 52 Week Low | $82.96 | |||
| Day High | $26.94 | P/E | 11.52 | |||
| Day Low | $24.87 | EPS | $2.24 | |||
| Volume | 1,300,770 | |||||
